Protection of renal cells from cisplatin toxicity by cell cycle inhibitors

被引:97
|
作者
Price, PM
Safirstein, RL
Megyesi, J
机构
[1] Univ Arkansas Med Sci, Dept Internal Med, Little Rock, AR 72205 USA
[2] Dept Vet Affairs Med Ctr, Little Rock, AR 72205 USA
关键词
kidney failure; p21 cyclin kinase inhibitor; roscovitine;
D O I
10.1152/ajprenal.00192.2003
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The optimal use of cisplatin as a chemotherapeutic drug has been limited by its nephrotoxicity. Murine models have been used to study cisplatin-induced acute renal failure. After cisplatin administration, cells of the S3 segment in the renal proximal tubule are especially sensitive and undergo extensive necrosis in vivo. Similarly, cultured proximal tubule cells undergo apoptosis in vitro after cisplatin exposure. We have shown in vivo that kidney cells enter the cell cycle after cisplatin administration but that cell cycle-inhibitory proteins p21 and 14-3-3sigma are also upregulated. These proteins coordinate the cell cycle, and deletion of either of the genes resulted in increased nephrotoxicity in vivo or increased cell death in vitro after exposure to cisplatin. However, it was not known whether cell cycle inhibition before acute renal failure could protect from cisplatin-induced cell death, especially in cells with functional p21 and 14-3-3sigma genes. Using several cell cycle inhibitors, including a p21 adenovirus, and the drugs roscovitine and olomoucine, we have been able to completely protect a mouse kidney proximal tubule cell culture from cisplatin-induced apoptosis. The protection by p21 was independent of an effect on the cell cycle and was likely caused by selective inhibition of caspase-dependent and -independent cell death pathways in the cells.
引用
收藏
页码:F378 / F384
页数:7
相关论文
共 50 条
  • [41] REDUCED RENAL ACCUMULATION AND TOXICITY OF CISPLATIN IN EXPERIMENTAL GALACTOSEMIA
    CACINI, W
    HARDEN, EA
    SKAU, KA
    PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1993, 203 (03): : 348 - 353
  • [42] Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer
    Welz, Stefan
    Hehr, Thomas
    Kollmannsberger, Christian
    Bokemeyer, Carsten
    Belka, Claus
    Budach, Wilfried
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (05): : 1429 - 1435
  • [43] CHRONIC-RENAL-FAILURE ATTRIBUTED TO CISPLATIN TOXICITY
    SIMO, R
    SANJOSE, A
    CARRERA, M
    SALAS, A
    BACHS, M
    TOVAR, JL
    NEFROLOGIA, 1986, 6 (02): : 103 - 106
  • [44] Cisplatin-induced renal toxicity in elderly people
    Duan, ZhiYu
    Cai, GuangYan
    Li, JiJun
    Chen, XiangMei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [45] CISPLATIN - A REVIEW OF CLINICAL-APPLICATIONS AND RENAL TOXICITY
    SLEIJFER, DT
    MEIJER, S
    MULDER, NH
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1985, 7 (06) : 237 - 244
  • [47] Innovator and generic cisplatin formulations: Comparison of renal toxicity
    Sekine, Ikuo
    Kubota, Kaoru
    Tamura, Yosuke
    Asahina, Hajime
    Yamada, Kazuhiko
    Horinouchi, Hidehito
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Tamura, Tomohide
    CANCER SCIENCE, 2011, 102 (01) : 162 - 165
  • [48] Low renal toxicity of lipoplatin compared to cisplatin in animals
    Devarajan, P
    Tarabishi, R
    Mishra, J
    Ma, Q
    Kourvetaris, A
    Vougiouka, M
    Boulikas, T
    ANTICANCER RESEARCH, 2004, 24 (04) : 2193 - 2200
  • [49] Hangeshashinto Increases the Resistance of Cells Against Cisplatin Cytotoxicity by Regulating the Cell Cycle
    Tamahara, Toru
    Arita, Ryutaro
    NATURAL PRODUCT COMMUNICATIONS, 2025, 20 (03)
  • [50] Heat-preconditioning confers protection from Ca2+-mediated cell toxicity in renal tubular epithelial cells (BSC-1)
    Kuhlmann, MK
    Betz, R
    Hanselmann, R
    Kohler, H
    CELL STRESS & CHAPERONES, 1997, 2 (03): : 175 - 179